PepGen presents EDO platform data for DM1 candidate PGN-EDODM1
PepGen Inc. released a May 2026 company presentation detailing clinical progress of its oligonucleotide therapy PGN-EDODM1 for myotonic dystrophy type 1, highlighting dose-dependent splicing correction from FREEDOM and FREEDOM2 trials. The company faces ongoing regulatory interac
View filing at SEC.gov →